Valneva Archives

News and Trends 5 Dec 2022

Positive antibody persistence for vaccine treating mosquito disease

A single shot vaccine for mosquito-borne disease chikungunya has had positive antibody persistence data 12 months after vaccination. The primary endpoint also met with a 99% seroresponse rate. The disease…

December 5, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2021

Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial

Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than…

October 26, 2021 - 5 minutesmins - By Victor Kotsev

Chikungunya vaccine clinical trial Valneva

News and Trends 19 Aug 2021

Chikungunya Vaccine First to Succeed in Phase III Trial

In a significant step in the fight against tropical disease, the mosquito-borne viral disease chikungunya may become preventable with a new vaccine candidate from French biotech Valneva that just passed…

August 19, 2021 - 3 minutesmins - By Victor Kotsev

dna sequencing covid 19 vaccine funding european biotech investment

News and Trends 10 Jun 2021

The Top European Biotech Investment Rounds in May

Last month saw huge biotech investment rounds dedicated to Covid-19 vaccines in Europe, including IPOs by Valneva and Vaccitech. However, a €227M (£195M) private round by the DNA sequencing giant…

June 10, 2021 - 4 minutesmins - By Jonathan Smith

News and Trends 7 May 2020

Lyme Disease Vaccine Gets Pfizer’s Backing in €284M Deal

The French biotech Valneva will collaborate with Pfizer to develop and commercialize Valneva’s phase II-stage Lyme disease vaccine candidate. The deal they signed is expected to help compensate for the…

May 7, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 18 Nov 2019

Update: Single-Shot Vaccine for Chikungunya Lasts for a Year in Phase I

Update (18/11/2019): French biotech Valneva has revealed additional phase I results concerning its experimental chikungunya vaccine; all 68 patients that were given a single injection of the vaccine showed sustained…

November 18, 2019 - 3 minutesmins - By Jonathan Smith

Interview 4 Sep 2019

Overcoming Clinical Setbacks to Fight Insect-Borne Diseases

Sometimes things don’t go your way in the biotech industry. The CEO of Valneva, Thomas Lingelbach, shared his experience of migrating from big pharma to biotech, and how his first…

September 4, 2019 - 9 minutesmins - By Jonathan Smith

More News! 20 Nov 2018

Phase I Gives Hope for First Zika Vaccine

Results from a Phase I trial showed promising safety and efficacy of a potential first vaccine against the mosquito-borne Zika virus, developed by French biotech Valneva and US biopharma Emergent…

November 20, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 12 Dec 2016

French Biotech Puts a New Lyme Disease Vaccine on the Horizon

There is currently no vaccine for the fast-growing disease in the US, & treatments cost over $1Bn every year. Valneva might have a vaccine to stem the tide. Valneva, a…

December 12, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 28 Aug 2015

[Update] Valneva’s duck stem cells attract two new Vaccine-deals

French Valneva continues to sign license agreements for its duck derived stem cell line that produces novel vaccines. Lyon-based Valneva was formed from the 70-year old duck breeder Group Grimaud. It…

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 18 Mar 2015

Valneva penetrates Chinese Market thanks to a license agreement

A few months ago, the article "An Anglo-French Partnership To Cure Hepatitis B" related Valneva partnerships with Immune Targeting Systems. Today Valneva, a leading pure play vaccines biotech company is…

March 18, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 31 Jan 2015

An Anglo-French Partnership To Cure Hepatitis B

European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. This deal grants ITS the rights to research,…

January 31, 2015 - 2 minutesmins - By Lourdes Riquelme

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering